IP Verse

Combination Of A Pd-1 Antagonist And A Vegfr Inhibitor For Treating Cancer - EP3498734

The patent EP3498734 was granted to Merck Sharp & Dohme on Sep 1, 2021. The application was originally filed on Feb 3, 2015 under application number EP18205542A. The patent is currently recorded with a legal status of "Revoked".

EP3498734

MERCK SHARP & DOHME
Application Number
EP18205542A
Filing Date
Feb 3, 2015
Status
Revoked
Jul 18, 2025
Grant Date
Sep 1, 2021
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (9)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

KONIG SZYNKA TILMANN VON RENESSEJun 1, 2022KONIG SZYNKA TILMANN VON RENESSE DUSSELDORFADMISSIBLE
KONIG SZYNKA TILMANN VON RENESSEJun 1, 2022KONIG SZYNKA TILMANN VON RENESSE PATENTANWALTE PARTNERSCHAFT MBB DUSSELDORFADMISSIBLE
PAJAROMay 31, 2022ALTADMISSIBLE
PAJAROMay 31, 2022BIRD & BIRDADMISSIBLE
POHLMANMay 31, 2022POHLMANADMISSIBLE
BOULT WADE TENNANTMay 27, 2022-ADMISSIBLE
SYMBIOSISMay 26, 2022SYMBIOSISADMISSIBLE
HOFFMANN EITLEMay 20, 2022-ADMISSIBLE
WUESTHOFF & WUESTHOFF PATENTANWALTE PARTG MBBMay 13, 2022WICHMANNADMISSIBLE

Patent Citations (40) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
DESCRIPTIONUS2004224988
DESCRIPTIONUS2006091067
DESCRIPTIONUS2006094763
DESCRIPTIONUS2007203196
DESCRIPTIONUS2008274192
DESCRIPTIONUS2011271358
DESCRIPTIONUS2014248347
DESCRIPTIONUS2014288125
DESCRIPTIONUS4816567
DESCRIPTIONUS6329511
DESCRIPTIONUS6534524
DESCRIPTIONUS6884890
DESCRIPTIONUS7141581
DESCRIPTIONUS7232910
DESCRIPTIONUS7488802
DESCRIPTIONUS7521051
DESCRIPTIONUS8008449
DESCRIPTIONUS8168757
DESCRIPTIONUS8354509
DESCRIPTIONUS8383796
DESCRIPTIONUS8791140
DESCRIPTIONWO2004004771
DESCRIPTIONWO2004056875
DESCRIPTIONWO2004072286
DESCRIPTIONWO2006048745
DESCRIPTIONWO2008156712
DESCRIPTIONWO2010027827
DESCRIPTIONWO2010077634
DESCRIPTIONWO2011066342
DESCRIPTIONWO2012135408
DESCRIPTIONWO2013019906
DESCRIPTIONWO2014100079
OPPOSITIONEP3102605
OPPOSITIONEP3498734
OPPOSITIONUS2004224988
OPPOSITIONWO2008156712
OPPOSITIONWO2012135408
OPPOSITIONWO2013181452
OPPOSITIONWO2014163684
OPPOSITIONWO2015119930

Non-Patent Literature (NPL) Citations (280) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference Text
DESCRIPTION- Agnew, Chem. Intl. Ed. Engl., (19940000), vol. 33, pages 183 - 186
DESCRIPTION- AHMADZADEH M et al., "Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired", Blood, (20090000), vol. 114, pages 1537 - 1544
DESCRIPTION- AL-LAZIKANI, JMB, (19970000), vol. 273, pages 927 - 948
DESCRIPTION- ALTSCHUL, S.F. et al., J. Mol. Biol., (19900000), vol. 215, pages 403 - 410
DESCRIPTION- ALTSCHUL, S.F. et al., J. Mol. Evol., (19930000), vol. 36, pages 290 - 300
DESCRIPTION- ALTSCHUL, S.F. et al., Nucleic Acids Res., (19970000), vol. 25, pages 3389 - 3402
DESCRIPTION- ALTSCHUL, S.F., J. Mol. Biol., (19910000), vol. 219, pages 555 - 565
DESCRIPTION- "A model of evolutionary change in proteins", DAYHOFF, M.O. et al., Atlas of Protein Sequence and Structure, Natl. Biomed. Res., (19780000), vol. 5, pages 345 - 352
DESCRIPTION- AUSBEL et al., Current Protocols in Molecular Biology, John Wiley and Sons, Inc., (20010000), vol. 1-4
DESCRIPTION- AUSUBEL et al., Current Protocols in Molecular Biology, John Wiley and Sons, Inc., (20010000), vol. 3
DESCRIPTION- BACA et al., J. Biol. Chem., (19970000), vol. 272, pages 10678 - 10684
DESCRIPTION- BAERT et al., New Engl. J. Med., (20030000), vol. 348, pages 601 - 608
DESCRIPTION- BARBAS, Nature Medicine, (19950000), vol. 1, pages 837 - 839
DESCRIPTION- BENIAMINOVITZ et al., New Engl. J. Med., (20000000), vol. 342, pages 613 - 619
DESCRIPTION- BioDirectory, Amersham Pharmacia Biotech, (20010000), pages 384 - 391
DESCRIPTION- CARPENTER et al., J. Immunol., (20000000), vol. 165, page 6205
DESCRIPTION- CHEN, B.J. et al., Clin Cancer Res, (20130000), vol. 19, pages 3462 - 3473
DESCRIPTION- CHOTHIA et al., J Mol. Biol., (19870000), vol. 196, pages 901 - 917
DESCRIPTION- CHOTHIA et al., Nature, (19890000), vol. 342, pages 877 - 883
DESCRIPTION- CHOTHIA et al., Nature, (19890000), vol. 342, pages 878 - 883
DESCRIPTION- CHOTHIA; LESK, J. Mol. Biol., (19870000), vol. 196, pages 901 - 917
DESCRIPTION- CLACKSON et al., Nature, (19910000), vol. 352, pages 624 - 628
DESCRIPTION- COLIGAN et al., Current Protcols in Immunology, John Wiley and Sons, Inc., (20010000), vol. 1
DESCRIPTION- COLIGAN et al., Current Protocols in Immunology, John Wiley, Inc., (20010000), vol. 4
DESCRIPTION- COLIGAN et al., Current Protocols in Protein Science, John Wiley and Sons, Inc., (20000000), vol. 1
DESCRIPTION- COLIGAN et al., Current Protocols in Protein Science, John Wiley and Sons, Inc., (20000000), vol. 2
DESCRIPTION- DE BRUIN et al., Nature Biotechnol., (19990000), vol. 17, pages 397 - 399
DESCRIPTION- DEMBO, A. et al., Ann. Prob., (19940000), vol. 22, pages 2022 - 2039
DESCRIPTION- EISENHAUER; E.A. et al., Eur. J Cancer, (20090000), vol. 45, pages 228 - 247
DESCRIPTION- "Evaluating the statistical significance of multiple distinct local alignments", ALTSCHUL, S.F., Theoretical and Computational Methods in Genome Research, Plenum, (19970000), pages 1 - 14
DESCRIPTION- EVERTS et al., J. Immunol., (20020000), vol. 168, pages 883 - 889
DESCRIPTION- FOLKMAN, Nature Med., (19950000), vol. 1, pages 27 - 31
DESCRIPTION- FOOTE; WINTER, J. Mol. Biol., (19920000), vol. 224, pages 487 - 499
DESCRIPTION- GADIOT, J. et al., Cancer, (20110000), vol. 117, pages 2192 - 2201
DESCRIPTION- GAO et al., "Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma", Clinical Cancer Research, (20090000), vol. 15, pages 971 - 979
DESCRIPTION- GHEBEH et al., "The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk propgnostic factors", Neoplasia, (20060000), vol. 8, pages 190 - 198
DESCRIPTION- GHEBEH H., "Foxp3+ tregs and B7-H1+/PD-1+ T lymphocytes co-infiltrate the tumor tissues of high-risk breast cancer patients: implication for immunotherapy", BMC Cancer, (20080223), vol. 8, page 57, XP021034690
DESCRIPTION- GHOSH et al., New Engl. J. Med., (20030000), vol. 348, pages 24 - 32
DESCRIPTION- GIBELLINI et al., J. Immunol., (19980000), vol. 160, pages 3891 - 3898
DESCRIPTION- GISH, W. et al., Nature Genet, (19930000), vol. 3, pages 266 - 272
DESCRIPTION- HAMANISHI J et al., "Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer", Proceeding of the National Academy of Sciences, (20070000), vol. 104, pages 3360 - 3365
DESCRIPTION- HANCOCK, J.M. et al., Comput. Appl. Biosci., (19940000), vol. 10, pages 67 - 70
DESCRIPTION- HARLOW; LANE, Antibodies A Laboratory Manual, Cold Spring Harbor Laboratory Press, (19880000), pages 139 - 243
DESCRIPTION- HE et al., J. Immunol., (19980000), vol. 160, page 1029
DESCRIPTION- HEIJNE, Eur. J. Biochem., (19830000), vol. 133, pages 17 - 21
DESCRIPTION- HENIKOFF, S. et al., Proc. Natl. Acad. Sci. USA, (19920000), vol. 89, pages 10915 - 10919
DESCRIPTION- HEROLD et al., New Engl. J. Med., (20020000), vol. 346, pages 1692 - 1698
DESCRIPTION- HINO et al., "Tumor cell expression of programmed cell death-1 is a prognostic factor for malignant melanoma", Cancer, (20100000), vol. 00, pages 1 - 9
DESCRIPTION- HOOGENBOOM; CHAMES, Immunol. Today, (20000000), vol. 21, pages 371 - 377
DESCRIPTION- HSING; BISHOP, J. Immunol., (19990000), vol. 162, pages 2804 - 2811
DESCRIPTION- HU-LOWE, D.D. et al., Clin Cancer Res, (20080000), vol. 14, pages 7272 - 7283
DESCRIPTION- INMAN et al., "PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression", Cancer, (20070000), vol. 109, pages 1499 - 1505
DESCRIPTION- KABAT, Adv. Prot. Chem., (19780000), vol. 32, pages 1 - 75
DESCRIPTION- KABAT et al., J. Biol. Chem., (19770000), vol. 252, pages 6609 - 6616
DESCRIPTION- KAITHAMANA et al., J. Immunol., (19990000), vol. 163, pages 5157 - 5164
DESCRIPTION- KARLIN, S. et al., Proc. Natl. Acad. Sci. USA, (19900000), vol. 87, pages 2264 - 2268
DESCRIPTION- KARLIN, S. et al., Proc. Natl. Acad. Sci. USA, (19930000), vol. 90, pages 5873 - 5877
DESCRIPTION- KOHLER et al., Nature, (19750000), vol. 256, page 495
DESCRIPTION- LE DOUSSAL et al., J. Immunol., (19910000), vol. 146, pages 169 - 175
DESCRIPTION- LIPSKY et al., New Engl. J. Med., (20000000), vol. 343, pages 1594 - 1602
DESCRIPTION- LIU et al., J. Neurol. Neurosurg. Psych., (19990000), vol. 67, pages 451 - 456
DESCRIPTION- MADDEN, T.L. et al., Meth. Enzymol., (19960000), vol. 266, pages 131 - 141
DESCRIPTION- MARKS et al., J. Mol. Biol., (19910000), vol. 222, pages 581 - 597
DESCRIPTION- "Matrices for detecting distant relationships", SCHWARTZ, R.M. et al., Atlas of Protein Sequence and Structure, Natl. Biomed. Res. Found., Washington, DC, (19780000), vol. 5, pages 353 - 358
DESCRIPTION- MENDEZ et al., Nature Genetics, (19970000), vol. 15, pages 146 - 156
DESCRIPTION- MENNE et al., Bioinformatics, (20000000), vol. 16, pages 741 - 742
DESCRIPTION- MENNE et al., Bioinformatics Applications Note, (20000000), vol. 16, pages 741 - 742
DESCRIPTION- MEYAARD et al., Immunity, (19970000), vol. 7, pages 283 - 290
DESCRIPTION- MILGROM et al., New Engl. J. Med., (19990000), vol. 341, pages 1966 - 1973
DESCRIPTION- "NCBI", Database accession no. NP 005009
DESCRIPTION- "NCBI", Database accession no. NP 054862
DESCRIPTION- "NCBI", Database accession no. NP 079515
DESCRIPTION- P. GOULD, International J. of Pharmaceutics, (19860000), vol. 33, pages 201 - 217
DESCRIPTION- PORTIELJI et al., Cancer Immunol. Immunother., vol. 52, pages 133 - 144
DESCRIPTION- PRESTA, J. Allergy Clin. Immunol., (20050000), vol. 116, page 731
DESCRIPTION- "Pro-drugs as Novel Delivery Systems", T. HIGUCHI; V. STELLA, A.C.S. Symposium Series, A.C.S. Symposium Series, (19870000), page 14
DESCRIPTION- Products for Life Science Research, Sigma-Aldrich, Co., (20010000), pages 45 - 89
DESCRIPTION- S. BERGE et al., Journal of Pharmaceutical Sciences, (19770000), vol. 66, no. 1, pages 1 - 19
DESCRIPTION- SHARPE, A.H; WHERRY, E.J.; AHMED R.; FREEMAN G.J., "The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection", Nature Immunology, (20070000), vol. 8, pages 239 - 245
DESCRIPTION- SHIMAUCHI T et al., "Augmented expression of programmed death-1 in both neoplasmatic and nonneoplastic CD4+ T-cells in adult T-cell Leukemia/ Lymphoma", Int. J. Cancer, (20070000), vol. 121, pages 2585 - 2590
DESCRIPTION- SLAMON et al., New Engl. J. Med., (20010000), vol. 344, pages 783 - 792
DESCRIPTION- SOLOWIEJ, S. et al., Biochemistry, (20090000), vol. 48, pages 7019 - 31
DESCRIPTION- STATES, D.J. et al., Methods, (19910000), vol. 3, pages 66 - 70
DESCRIPTION- TANG et al., J. Biol. Chem., (19990000), vol. 274, pages 27371 - 27378
DESCRIPTION- TAUBE, J. M. et al., Sci Transl Med, (20120000), vol. 4, page 127ra37
DESCRIPTION- The Orange Book, Food & Drug Administration
DESCRIPTION- THOMPSON, R. H. et al., Cancer Res., (20060000), vol. 66, pages 3381 - 3385
DESCRIPTION- THOMPSON RH et al., "PD-1 is expressed by tumor infiltrating cells and is associated with poor outcome for patients with renal carcinoma", Clinical Cancer Research, (20070000), vol. 15, pages 1757 - 1761
DESCRIPTION- THOMPSON, R. H. et al., PNAS, (20040000), vol. 101, no. 49, pages 17174 - 17179
DESCRIPTION- TOPLIAN, S. L. et al., New Eng. J Med., (20120000), vol. 366, no. 26, pages 2443 - 2454
DESCRIPTION- VAUGHAN et al., Nature Biotechnol., (19960000), vol. 14, pages 309 - 314
DESCRIPTION- VON HEIJNE, Nucleic Acids Res., (19860000), vol. 14, pages 4683 - 4690
DESCRIPTION- WATSON et al., Molecular Biology of the Gene, The Benjamin/Cummings Pub. Co., (19870000), page 224
DESCRIPTION- W. A. WEBER, J. Nucl. Med., (20090000), vol. 50, pages 1S - 10S
DESCRIPTION- WHO Drug Information, (20130000), vol. 27, no. 1, pages 68 - 69
DESCRIPTION- WHO Drug Information, (20130000), vol. 27, no. 2, pages 161 - 162
DESCRIPTION- WOOTTON, J.C. et al., Comput. Chem., (19930000), vol. 17, pages 149 - 163
DESCRIPTION- WREN et al., Comput. Methods Programs Biomed., (20020000), vol. 68, pages 177 - 181
DESCRIPTION- WRIGHT et al., Immunity, (20000000), vol. 13, pages 233 - 242
DESCRIPTION- WU, Recombinant DNA, Academic Press, (19930000), vol. 217
DESCRIPTION- YANG et al., New Engl. J. Med., (20030000), vol. 349, pages 427 - 434
DESCRIPTION- YANG et al., "PD-1 interaction contributes to the functional suppression of T-cell responses to human uveal melanoma cells in vitro", Invest Ophthalmol Vis Sci, (20080600), vol. 49, no. 49, pages 2518 - 2525
DESCRIPTION- ZHANG, J. et al., Genome Res., (19970000), vol. 7, pages 649 - 656
DESCRIPTION- NAKANISHI J., "Overexpression of B7-H1 (PD-L1) significantly associates with tumor grade and postoperative prognosis in human urothelial cancers", Cancer Immunol Immunother, (20070000), vol. 56, doi:doi:10.1007/s00262-006-0266-z, pages 1173 - 1182, XP019514169
DESCRIPTION- DONG H et al., "Tumor-associated B7-Hl promotes T-cell apoptosis: a potential mechanism of immune evasion", Nat Med., (20020800), vol. 8, no. 8, doi:doi:10.1038/nm730, pages 793 - 800, XP002397368
DESCRIPTION- OHIGASHI Y et al., "Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand 2 expression in human esophageal cancer", Clin. Cancer Research, (20050000), vol. 11, doi:doi:10.1158/1078-0432.CCR-04-1469, pages 2947 - 2953, XP002419631
DESCRIPTION- NOMI, T.; SHO, M.; AKAHORI, T. et al., "Clinical significance and therapeutic potential of the programmed death- 1 ligand/programmed death-1 pathway in human pancreatic cancer", Clinical Cancer Research, (20070000), vol. 13, doi:doi:10.1158/1078-0432.CCR-06-2746, pages 2151 - 2157, XP002533527
DESCRIPTION- THOMPSON RH et al., "Significance of B7-H1 overexpression in kidney cancer", Clinical genitourin Cancer, (20060000), vol. 5, doi:doi:10.3816/CGC.2006.n.038, pages 206 - 211, XP009114210
OPPOSITION- Anonymous, "A Dose Finding Study To Evaluate Safety, Drug Interaction, Tumor Markers Of Axitinib In Combination With MK -3475 In Adult Patients With Previously Untreated Advanced Renal Cell Cancer", ClinicalTrials.gov Identifier: NCT02133742, (20140508), pages 1 - 12, XP055930845
OPPOSITION- Anonymous, "A Study of Pembrolizumab ( MK -3475) in Combination With Chemotherapy or Immunotherapy in Participants With Non-small Cell Lung Cancer ( MK -3475- 021/KEYNOTE-021", CLINICALTRIALS.GOV ARCHIVE NCT02039674, (20140117), pages 1 - 5, XP055931009
OPPOSITION- Anonymous, "Clinical Development Success Rates 2006-2015", BIO, Biomedtracker, Amplion, (20180202), pages 1 - 28, XP055931063
OPPOSITION- Anonymous, "HIGHLIGHTS OF PRESCRIBING INFORMATION INLYTA® (axitinib) tablets for oral administration", U.S Food and Drug Administration, (20120101), pages 1 - 22, XP055926905
OPPOSITION- Anonymous, "HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use KEYTRUDA safely and effectively. See full prescribing information for KEYTRUDA.", (20140101), (20220608), XP055928658
OPPOSITION- Anonymous, "History Changes for Study: NCT02331368 Phase 2 Multi-center Study of Anti-PD-1 During Lymphopenic State After HDT/ASCT for Multiple Myeloma", CLINICALTRIALS.GOV ARCHIVE NCT02331368, (20150100), pages 1 - 4, XP055931028
OPPOSITION- Anonymous, "History Changes for Study: NCT02331368 Phase 2 Multi-center Study of Anti-PD-1 During Lymphopenic State After HDT/ASCT for Multiple Myeloma", CLINICALTRIALS.GOV ARCHIVE NCT02331368, (20150101), pages 1 - 4, CLINICALTRIALS.GOV ARCHIVE NCT02331368 , (20220614), XP055931028
OPPOSITION- Anonymous, "History of Changes for Study: NCT01295827 Study of MK-3475 in Participants With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, or Non-small C Carcinoma (P07990/MK-3475-001)", Clinicaltrials.gov NCT01295827, (20140130), Clinicaltrials.gov NCT01295827, URL: https://www.clinicaltrials.gov/ct2/history/NCT01295827?V_42=View#StudyPageTop, (20220628), XP055935954
OPPOSITION- Anonymous, "History of Changes for Study: NCT01472081 Nivolumab (BMS-936558; MDX-1106) in Combination With Sunitinib, Pazopanib, or Ipilimumab in Subjects With Metastatic Renal Cell Carcinoma (RCC) (CheckMate 016)", CLINICALTRIALS.GOV NCT01472081, (20140117), CLINICALTRIALS.GOV NCT01472081, URL: https://clinicaltrials.gov/ct2/history/NCT01472081?V_29=View#StudyPageTop, (20220628), XP055935981
OPPOSITION- Anonymous, "History of Changes for Study: NCT01472081. Nivolumab (BMS-936558; MDX-1106) in Combination With Sunitinib, Pazopanib, or Ipilimumab in Subjects With Metastatic Renal Cell Carcinoma (RCC) (CheckMate 016) D37a", Clinical Trials.gov NCT01472081, (20111111), Clinical Trials.gov NCT01472081, URL: https://clinicaltrials.gov/ct2/history/NCT01472081?V_23=View, (20220624), XP055935170
OPPOSITION- Anonymous, "History of Changes for Study: NCT01704287 Study of MK-3475 Versus Chemotherapy in Participants With Advanced Melanoma", Clinicaltrials.gov NCT01704287, (20131231), Clinicaltrials.gov NCT01704287, URL: https://clinicaltrials.gov/ct2/history/NCT01704287?V_21=View#StudyPageTop, (20220628), XP055935961
OPPOSITION- Anonymous, "History of Changes for Study: NCT01984242 A Study of Atezolizumab (an Engineered Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) as Monotherapy or in Combination With Bevacizumab (Avastin®) Compared to Sunitinib (Sutent®) in Participants With Untreated Advanced Renal Cell Carcinoma (IMmotion150) D54", Clinical Trials.gov NCT01984242, (20131107), Clinical Trials.gov NCT01984242, URL: https://clinicaltrials.gov/ct2/history/NCT01984242, (20220624), XP055935149
OPPOSITION- Anonymous, "History of Changes for Study: NCT02014636 Safety and Efficacy Study of Pazopanib and MK 3475 in Advanced Renal Cell Carcinoma (RCC)", Clinical Trials.gov, (20131212), pages 1 - 7, Clinical Trials.gov, URL: https://clinicaltrials.gov/ct2/history/NCT02014636?A=1&B=1&C=merged#StudyPageTop, (20220601), XP055926897
OPPOSITION- Anonymous, "History of Changes for Study: NCT02014636 Safety and Efficacy Study of Pazopanib and MK 3475 in Advanced Renal Cell Carcinoma (RCC)", CLINICALTRIALS.GOV NCT02133742, (20130123), CLINICALTRIALS.GOV NCT02133742 , URL: https://clinicaltrials.gov/ct2/history/NCT02014636?V_4=View#StudyPageTop, (20220628), XP055935971
OPPOSITION- Anonymous, "History of Changes for Study: NCT02036502 A Study of Pembrolizumab ( MK -3475) in Combination With in Participants With Multiple Myeloma ( MK -3475-023/KEYNOTE-023)", CLINICALTRIALS.GOV ARCHIVE NCT02036502, (20180424), pages 1 - 11, XP055931117
OPPOSITION- Anonymous, "History of Changes for Study: NCT02039674. A Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy or Immunotherapy in Participants With Non-small Cell Lung Cancer (MK-3475-021/KEYNOTE-021) D53a", Clinical Trials.gov NCT02039674, (20140116), Clinical Trials.gov NCT02039674, URL: https://clinicaltrials.gov/ct2/history/NCT02039674, (20220624), XP055935145
OPPOSITION- Anonymous, "History of Changes for Study: NCT02133742 A Dose Finding Study To Evaluate Safety, Drug Interaction, Tumor Markers Of Axitinib In Combination With MK-3475 In Adult Patients With Previously Untreated Advanced Renal Cell Cancer", CLINICALTRIALS.GOV ARCHIVE, (20140506), pages 1 - 3, CLINICALTRIALS.GOV ARCHIVE, URL: https://clinicaltrials.gov/ct2/history/NCT02133742, (20220601), XP055926894
OPPOSITION- Anonymous, "History of Changes for Study: NCT02133742 A Dose Finding Study To Evaluate Safety, Drug Interaction, Tumor Markers Of Axitinib In Combination With MK-3475 In Adult Patients With Previously Untreated Advanced Renal Cell Cancer", CLINICALTRIALS.GOV ARCHIVE, (20140508), pages 1 - 3, CLINICALTRIALS.GOV ARCHIVE, URL: https://clinicaltrials.gov/ct2/history/NCT02133742, (20220601), XP055926894
OPPOSITION- Anonymous, "History of Changes for Study: NCT02133742 A Dose Finding Study To Evaluate Safety, Drug Interaction, Tumor Markers Of Axitinib In Combination With MK-3475 In Adult Patients With Previously Untreated Advanced Renal Cell Cancer", CLINICALTRIALS.GOV ARCHIVE, (20140508), pages 1 - 3, XP055926894
OPPOSITION- Anonymous, "Lambrolizumabum # Lambrolizumab", WHO Drug Information, (20130101), vol. 27, no. 2, pages 95 - 96, 161-162, XP055935957
OPPOSITION- Anonymous, "Merck withdraws keytruda from SCLC indication amid FDA crackdown ", clinical trials arena, (20210303), clinical trials arena , (20220531), XP055926233
OPPOSITION- Anonymous, "Merck withdraws keytruda from SCLC indication amid FDA crackdown ", clinical trials arena, (20210303), clinical trials arena , URL: https://www.clinicaltrialsarena.com/news/merck-withdraws-keytruda-for-lung-cancer-amid-fda-crackdown/#:~:text=On%201%20March%2C%20Merck%20announced,other%20prior%20line%20of%20therapy., (20220531), XP055926233
OPPOSITION- Anonymous, "NCT01295827 study of MK-3475 in participants with progressive locally advanced or metastatic carcinoma , melanoma or non small cell lung carcinoma (P07990/MK-3475-001)", CLINICALTRIALS.GOV, (20140130), XP055926241
OPPOSITION- Anonymous, "NCT01704287 studt of MK-3475 versus chemotherapy in participants with advanced melanoma ", clinicaltrails.gov, (20131231), clinicaltrails.gov , (20220531), XP055926238
OPPOSITION- Anonymous, "NCT02014636 A Phase I/II Study to Assess the Safety and Efficacy of Pazopanib and MK 3475 in Subjects With Advanced Renal Cell Carcinoma", Clinical Trials.gov, (20140124), pages 1 - 11, Clinical Trials.gov, URL: https://clinicaltrials.gov/archive/NCT02014636/2014_01_24, (20150331), XP055180536
OPPOSITION- Anonymous, "Nivolumab (BMS 936558, MD -1106) in combination with sunitinib, pazopanib, or ipilimumab in subjects with metastatic renal cell carcinoma (RCC).", ClinicalTrials.gov Identifier: NCT01472081, (20111111), pages 1 - 11, XP055439042
OPPOSITION- Anonymous, "Safety and Efficacy Study of Pazopanib and MK 3475 in Advanced Renal Cell Carcinoma (RCC; KEYNOTE-018)", ClinicalTrials.gov Identifier: NCT02014636, (20131218), pages 1 - 10, XP055930838
OPPOSITION- Anonymous, "special issue abstracts of the thritheenth international kidney cancer symposium ", BJUI international, (20141024), vol. 114, no. s4, XP055928393
OPPOSITION- Anonymous, "Study Record Versions History of Changes for Study: NCT01472081 Nivolumab (BMS-936558; MDX-1106) in Combination With Sunitinib, Pazopanib, or Ipilimumab in Subjects With Metastatic Renal Cell Carcinoma (RCC) (CheckMate016)", Clinical Trials.gov, (20140117), Clinical Trials.gov, (20220607), XP055928385
OPPOSITION- Anonymous, "update 1-pfizer pancreatic cancer drug fails trial halted ", Reuters, (20090201), Reuters, (20220531), XP055926232
OPPOSITION- Anonymous, "WHO Drug Information", WHO, (20130101), vol. 27, no. 2, pages 95, 96 - 161, 162, XP055632276
OPPOSITION- ASIM AMIN et al., "High-Dose Interleukin-2: It Still Indicated for Melanoma and RCC in an Era of Targeted Therapies?", Oncology, (20130705), vol. 27, no. 7, pages 1 - 13, XP055930863
OPPOSITION- CHOUEIRI et al., "Trial in progress: phase 1b dose-finding study of axitinib plus pembrolizumab for first-line treatment of advanced renal cell carcinoma (RCC", BJU International, (20141021), vol. 114, no. 4, pages 1 - 18, XP055632141
OPPOSITION- CHOUEIRI et al., "Trial in progress: Phase 1b dose-finding study of axitinib plus pembrolizumab for first line treatment of advanced renal cell carcinoma (RCC", BJU International, (20141021), vol. 114, no. S4, pages 4 - 5, XP055632141
OPPOSITION- Choueiri, Et Al., "Trial in progress: phase 1b dose-finding study of axitinib plus pembrolizumab for the first-line treatment of advanced renal cell carcinoma (RCC)", (20141021), vol. 114, no. S4, pages 4 - 5, XP055632141
OPPOSITION- Clinicaltrials, "NCT02133742, A Dose Finding Study To Evaluate Safety, Drug Interaction, Tumor Markers Of Axitinib In Combination With MK-3475 In Adult Patients With Previously Untreated Advanced Renal Cell Cancer", ClinicalTrials.gov archive, (20140705), ClinicalTrials.gov archive, URL: https://clinicaltrials.gov/archive/NCT02133742/2014_05_07, (20150330), XP055180147
OPPOSITION- Czarnecka A L, Solarek W, Hakimi Aa, Fiegoli B, Zabor Ec, Bernstein M, Furberg-Barnes Ah, Russo P, "Abstracts", BJU International. The 11th International Kidney Cancer Symposium Annual Meeting Proceedings, (20120101), vol. 110, no. 2S, pages 1 - 20, XP055935178
OPPOSITION- DOLOFF AND WAXMAN, "VEGF Receptor Inhibitors Block the Ability of Metronomically Dosed Cyclophosphamide to Activate Innate Immunity-Induced Tumor Regression", Cancer Research, (20120111), vol. 72, no. 5, pages 1103 - 1115, XP055928654
OPPOSITION- Drabkin Harry A, "Open Access Journal of Urology Pazopanib and anti-VEGF therapy Introduction to VEGF biology and anti-VEGF therapy", Open Access Journal of Urology, (20100311), vol. 2, pages 35 - 40, XP055935184
OPPOSITION- FRIEDMAN et al., "Fundamentals of Clinical Trial 4th Edition", Chapter 1, Springer, (20100000), pages 21 - 27, XP055931052
OPPOSITION- HUTSON et al., "Axitinib versus sorafenib as first-line therapy in patients with metastatic renal cell carcinoma: a randomised open label phase 3 trial", Lancet Oncol, (20130000), vol. 14, no. 13, pages 1287 - 94, XP055892151
OPPOSITION- HUTSON et al., "Axitinib versus sorafenib as first-line therapy in patients with metastatic renal- cell carcinoma: a randomised open-label phase 3 trial.", Lancet Oncology, (20131025), vol. 14, pages 1287 - 1294
OPPOSITION- Hutson Thomas E, Lesovoy Vladimir, Al-Shukri Salman, Stus Viktor P, Lipatov Oleg N, Bair Angel H, Rosbrook Brad, Chen Connie, Kim Sinil, Vogelzang Nicholas J, "Axitinib versus sorafenib as fi rst-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial", (20131201), pages 1287 - 1294, URL: https://www.sciencedirect.com/science/article/pii/S1470204513704650/pdfft?md5=a406b70f44e19594098ae772da9add4e&pid=1-s2.0-S1470204513704650-main.pdf, (20220215), XP055892151
OPPOSITION- "Immunoglobulin G4, anti-(human protein PDCD1 (programmed cell death 1)) (human-Mus musculus monoclonal heavy chain), disulfide with human-Mus musculus monoclonal light chain, dimer (CA INDEX NAME)", Registry, (20120531), Database accession no. 1374853-91-4, URL: STN, XP055935221
OPPOSITION- JIE MA AND WAXMAN, "Modulation of the antitumor activity of metronomic cyclophosphamide by the angiogenesis inhibitor axitinib.", Mol. Cancer Ther., (20080100), vol. 7, no. 1, pages 79 - 89, XP055928652
OPPOSITION- Jie Ma, David J.Waxman , "Modulation of the antitumor activity of metronomic cyclophosphamide by the angiogenesis inhibitor axitinib.", Mol. Cancer Ther., (20080101), vol. 7, no. 1, pages 70 - 89, XP055928652
OPPOSITION- Jushua C. Doloff, David J.Waxman , "VEGF Receptor Inhibitors Block the Ability of Metronomically Dosed Cyclophosphamide to Activate Innate Immunity-Induced Tumor Regression", Cancer Research, (20101004), pages 1103 - 1115, XP055928654
OPPOSITION- Jushua C. Doloff, David J.Waxman , "VEGF Receptor Inhibitors Block the Ability of Metronomically Dosed Cyclophosphamide to Activate Innate Immunity-Induced Tumor Regression", Cancer Research, (20120111), pages 1103 - 1115, XP055928654
OPPOSITION- KAUFMAN et al., "The society for immunotherapy of cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma", Nature Reviews Clinical Oncology, (20130000), vol. 10, pages 588 - 598, XP055930974
OPPOSITION- LOGAN et al., "Systemic Therapy for Metastatic Renal Cell Carcinoma: A Review and Update", Rev Urol, (20110000), vol. 14, no. 3/4, pages 65 - 78, XP055930938
OPPOSITION- MAHAN V.L., "Clinical Trial Phases", International Journal of Clinical Medicine, (20141200), vol. 5, no. 21, pages 1374 - 1383, XP055931058
OPPOSITION- Merck, "HIGHLIGHTS OF PRESCRIBING INFORMATION. KEYTRUDA® (pembrolizumab) for injection, for intravenous use", FDA, (20140901), FDA, (20220628), XP055935969
OPPOSITION- "NCT02014636 A phase I/II study to assess the safety and efficacy of pazopanib and MK 3475 in subjects with advanced renal cell carcinoma", Clinical Trials.gov, (20131200), XP055180536
OPPOSITION- "NCT02133742 A dose finding study to evaluate safety, drug interaction, tumor markers of Axitinib in combination with MK - 3475 in adult patients with previously untreated advanced renal cell cancer", Clinical Trials.gov archive, (20140506), XP055180147
OPPOSITION- NCT2014636 A Phase I/II Study to Assess the Safety and Efficacy of Pazopanib and MK -3475 in Subjects with Advanced Renal Cell Carcinoma, (20140123), URL: ClinicalTrials.gov, XP055180536
OPPOSITION- Patel, Et Al., "Clinical cancer advances 2013: Annual report on progress against cancer from the American society of clinical oncology", J. Clin. Oncol., (20131210), vol. 31, pages 1 - 33, XP055632195
OPPOSITION- PATEL et al., "Clinical cancer advances 2013: Annual report on progress against cancer from the American society of clinical oncology", J. Clin. Oncol., (20131210), vol. 31, pages 1 - 33, XP055632195
OPPOSITION- PATNAIK et al., "Phase I study of MK -3475 (anti-PD-1 monoclonal antibody) in patients with advanced solid tumors", J. Clin. Oncol., (20120520), vol. 15, XP0055831683
OPPOSITION- PATNAIK et al., "Phase I study of MK -3475 (anti-PD-1 monoclonal antibody) in patients with advanced solid tumors", Journal of Clinical Oncology, (20120520), vol. 30, no. 15, XP055831683
OPPOSITION- Pfizer, "Pfizer and Merck to collaborate on innovative anti-cancer combination studies", EPR European Pharmaceutical Review, (20140205), pages 1 - 5, URL: https://www.europeanpharmaceuticalreview.com/news/23916/pfizer-merck-collaborate-innovative-anti-cancer-combination-studies, XP055930880
OPPOSITION- Rini Brian, Bernard Escudier, Piotr Tomczak, Andrey Kaprin, Cezary Szczylik, Thomas E Hutson, M Dror Michaelson, Vera A Gorbunova, Martin E Gore, Igor G Rusakov, Sylvie Negrier, Yen-Chuan Ou, Daniel Castellano, Ho Yeong Lim, Hirotsugu Uemura, Jamal Tarazi, David Cella, Connie Chen, Brad Rosbrook, Sinil Kim, Robert J Motze, "Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial", Lancet Published Online November, (20111209), pages 1931 - 1939, Lancet Published Online November, URL: https://www.sciencedirect.com/science/article/pii/S0140673611616139/pdfft?md5=2ed2543ae7cbe4e7662386c5a1665fbb&pid=1-s2.0-S0140673611616139-main.pdf, (20220215), XP055892144
OPPOSITION- RINI et al., "Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial", Lancet, (20111104), vol. 378, pages 1931 - 39
OPPOSITION- Rini R., Viktor Grünwald, Mayer N Fishman,Melichar Bohuslav, Ueda Takeshi, A.H. Bair, Chen Ying, Paul W. Bycott, Dmitri Pavlov, Sinil Kim, Eric Jonasch, "Axitinib with or without dose titration for first-line metastatic renal cell carcinoma (mRCC): Unblended results from a randomized phase II study", J Clin Oncol, (20130220), vol. 31, no. 6S, page LBA349, XP055935208
OPPOSITION- ROBERT et al., "LBA34 - Pembrolizumab (pembro; MK -3475) for advanced melanoma: Randomized comparison of two dosing schedules", Annals of Oncology, (20140929), vol. 25, no. 5, pages 1 - 41, XP055632262
OPPOSITION- ROBERT et al., "LBA - Pembrolizumab (pembro; MK -3475) for advanced melanoma: Randomized comparison of two dosing schedules", Annals of Oncology, (20140929), vol. 25, no. 5, pages 1 - 41, XP055632262
OPPOSITION- TANG AND HENG, "Programmed Death 1 Pathway Inhibition in Metastatic Renal Cell Cancer and Prostate Cancer", Current Oncology Reports, (20121222), vol. 15, no. 2, pages 98 - 104, XP055632325
OPPOSITION- TANG et al., "Programmed Death 1 Pathway Inhibition in Metastatic Renal Cell Cancer and Prostate Cancer", Current Oncology Reports, (20130000), vol. 15, no. 2, pages 98 - 104, XP055632325
OPPOSITION- TANG et al., "Programmed death 1 pathway inhibition in metastatic renal cell cancer and prostate cancer", Curr Oncol Rep, (20121222), vol. 15, no. 2, pages 98 - 104, XP055632325
OPPOSITION- David F. Mcdermott, Michael B. Atkins, "PD-1 as a potential target in cancer therapy", Cancer Medicine, Wiley, (20130721), doi:10.1002/cam4.106, ISSN 20457634, pages 662 - 673, XP055157252
OPPOSITION- David F. Mcdermott, Michael B. Atkins, "PD-1 as a potential target in cancer therapy", Cancer Medicine, Wiley, (20130721), doi:10.1002/cam4.106, ISSN 20457634, pages n/a - n/a, XP055157252
OPPOSITION- David F. Mcdermott, Michael B. Atkins, "PD-1 as a potential target in cancer therapy", Cancer Medicine, Wiley, (20130721), vol. 2, no. 5, doi:10.1002/cam4.106, ISSN 20457634, pages 662 - 673, XP055157252
OPPOSITION- Mcdermott David F., Atkins Michael B., "PD-1 as a potential target in cancer therapy", Cancer Medicine, (20130721), pages 662 - 673, XP055157252
OPPOSITION- MCDERMOTT et al., "PD-1 as a potential target in cancer therapy", Cancer Med, (20130721), pages 662 - 673, XP055157252
OPPOSITION- MCDERMOTT et al., "PD-1 as a potential target in cancer therapy", Cancer Med., (20130721), pages 662 - 673, XP055157252
OPPOSITION- Brian I. Rini; Mark Stein; Pat Shannon; Simantini Eddy; Allison Tyler; Joe J. Stephenson; Lorie Catlett; Bo Huang; Diane Healey; Michael Gordon, "Phase 1 dose‐escalation trial of tremelimumab plus sunitinib in patients with metastatic renal cell carcinoma", Cancer, American cancer society , Philadelphia , PA, US, US , (20101004), vol. 117, no. 4, doi:10.1002/cncr.25639, ISSN 0008-543X, pages 758 - 767, XP071175919
OPPOSITION- Lindauer A, Et Al, "Translational Pharmacokinetic/Pharmacodynamic Modeling of Tumor Growth Inhibition Supports Dose-Range Selection of the Anti-PD-1 Antibody Pembrolizumab", CPT: Pharmacometrics & Systems Pharmacology, Wiley Blackwell, (20170101), vol. 6, no. 1, doi:10.1002/psp4.12130, ISSN 2163-8306, pages 11 - 20, XP093218990
OPPOSITION- Bernard Escudier, Martin Gore, "Axitinib for the Management of Metastatic Renal Cell Carcinoma", Drugs in R&D, (20110601), vol. 11, no. 2, doi:10.1007/BF03259801, ISSN 11745886, pages 113 - 126, XP055180526
OPPOSITION- ESCUDIER AND GORE, "Axitinib for the Management of Metastatic Renal Cell Carcinoma", Drugs in R&D, (20110601), vol. 11, no. 2, doi:10.1007/BF03259801, pages 113 - 126, XP055180526
OPPOSITION- ESCUDIER et al., "Axitinib for the management of metastatic renal cell carcinoma", Drugs in R&D, (20110000), vol. 11, no. 2, doi:10.1007/BF03259801, pages 113 - 126, XP055180526
OPPOSITION- ESCUDIER et al., "Axitinib for the Management of Metastatic Renal Cell Carcinoma", Drugs In R&D, (20110601), vol. 11, no. 2, doi:10.1007/BF03259801, pages 113 - 126, XP055180526
OPPOSITION- ESCUDIER et al., "Axitinib for the Management of Metastatic Renal Cell Carcinoma", Drugs in R&D., vol. 11, no. 2, doi:10.1007/BF03259801, pages 113 - 126, XP055180526
OPPOSITION- ESCUDIER et al., "Axitinib for the Management of Metastatic Renal Cell Carcinoma", Drugs R D, (20110600), vol. 11, no. 2, doi:10.1007/BF03259801, pages 113 - 126, XP055180526
OPPOSITION- ESCUDIER et al., "Optimal Management of Metastatic Renal Cell Carcinoma: Current Status", Drugs, vol. 73, no. 5, doi:10.1007/s40265-013-0043-1, pages 42 - 438, XP055632312
OPPOSITION- ESCUDIER et al., "Optimal Management of Metastatic Renal Cell Carcinoma", Drugs, (20130410), vol. 73, no. 5, doi:10.1007/s40265-013-0043-1, pages 427 - 438, XP055632312
OPPOSITION- ESCUDIER et al., "Optimal managment of metastatic renal cell carcinoma: Current status", Drugs, (20130410), vol. 73, no. 5, doi:10.1007/s40265-013-0043-1, pages 427 - 438, XP055632312
OPPOSITION- RINI et al., "Five-year survival in patients with cytokine refractory metastatic renal cell carcinoma treated with axitinib", Clinical Genitourinary Cancer, (20130600), vol. 11, no. 2, doi:10.1016/j.clgc.2012.12.004, pages 107 - 114, XP055632267
OPPOSITION- RINI et al., "Five-year survival in patients with cytokine-refractory metastatic renal cell carcinoma treated with axitinib", Clinical Genitourinary Cancer, (20130600), vol. 11, no. 2, doi:10.1016/j.clgc.2012.12.004, pages 107 - 114, XP055632267
OPPOSITION- Chowdhury Simon, Infante Jeffery R, Hawkins Robert, Voss Martin H, Perini Rodolfo, Arkenau Tobias, Voskoboynik Mark, Aimone Paola, Naeije Isabelle, Reising Albert, Mcdermott David F, "A Phase I/II Study to Assess the Safety and Efficacy of Pazopanib and Pembrolizumab Combination Therapy in Patients with Advanced Renal Cell Carcinoma", Clinical Genitourinary Cancer, (20210000), vol. 19, no. 5, pages 434 - 446, XP055931144
OPPOSITION- ROBERT et al., "Drug of the year: programmed death-1 receptor/programmed death-1 ligand-1 receptor monoclonal antibodies.", Eur. J. Cancer, (20130729), vol. 49, no. 14, doi:10.1016/j.ejca.2013.07.001, pages 2968 - 2971, XP055632318
OPPOSITION- ROBERT et al., "Drug of the year: Programmed death-1 receptor/programmed death-1 ligand-1 receptor monoclonal antibodie s", Eur J Cancer, (20130729), vol. 49, no. 14, doi:10.1016/j.ejca.2013.07.001, pages 2968 - 2971, XP055632318
OPPOSITION- ROBERT et al., "Drug of the year: programmed death-1 receptor/programmed death-1 ligand-1 receptor monoclonal antibodies", Eur. J. Cancer, vol. 49, no. 14, doi:10.1016/j.ejca.2013.07.001, pages 2968 - 71, XP055632318
OPPOSITION- Balmanoukian A.S.; Rizvi N.A.; Garon E.B.; Patnaik A.; Gandhi L.; Leighl N.B.; Goldman J.W.; Eder J.P.; Johnson E.A.; Blumenschein G.R.; Gubens M.A.; Papadopoulos K.P.; Lubiniecki G.M.; Zhang J.; Niewood M.; Emancipator K.; Dolled-Filhart M.; Hanson M.E.; Hui R., "Safety and Clinical Activity of MK-3475 as Initial Therapy in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Novel Therapies/Experimental Therapies", INTERNATIONAL JOURNAL OF RADIATION: ONCOLOGY BIOLOGY PHYSICS., PERGAMON PRESS., USA, USA , (19000101), vol. 90, no. 5, doi:10.1016/j.ijrobp.2014.08.023, ISSN 0360-3016, page 8007, XP029091305
OPPOSITION- Kindler Hedy L., Tatsuya Ioka, Dirk J Richel, Jaafar Bennouna, Richard Létourneau, Takuji Okusaka, Takuji, Funakoshi Akihiro, Furuse Junji, Park Young Suk, Ohkawa Shinichi, Springett Gregory M, Wasan Harpreet S, Trask Peter C, Bycott Paul, Ricart Alejandro D, Kim Sinil, Cutsem Eric Van, "Axitinib plus gemcitabine versus placeboplus gemcitabine in patients with advanced pancreatic adenocarcinoma: A double-blind randomised phase 3 study", Lancet Oncol Published Online February, (20110301), vol. 12, no. 8, doi:10.1016/S1470, pages 256 - 262, XP055935167
OPPOSITION- KINDLER et al., "Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study", Lancet Oncol., (20110300), vol. 12, no. 3, pages 256 - 62, XP055928437
OPPOSITION- Rini Brian I, Melichar Bohuslav, Ueda Takeshi, Grünwald Viktor, Fishman Mayer N, Arranz José A, Bair Angel H, Pithavala Yazdi K, Andrews Glen I, Pavlov Dmitri, Kim Sinil, Jonasch Eric, "Axitinib with or without dose titration for first-line metastatic renal- cell carcinoma: a randomised double-blind phase 2 trial", Lancet Oncol, (20131100), vol. 14, no. 12, pages 1233 - 1242, XP055930932
OPPOSITION- ATKINS et al., "Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: A non-randomised, open-label, dose-finding, and dose-expansion phase 1 b trial", Lancet Oncol, (20180000), vol. 19, no. 3, doi:10.1016/S1470-2045(18)30081-0, pages 405 - 415, XP085355809
OPPOSITION- ATKINS et al., "Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial.", Lancet Oncol., (20180210), vol. 19, no. 3, doi:10.1016/S1470-2045(18)30081-0, pages 405 - 415, XP085355809
OPPOSITION- ATKINS et al., "Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial", Lancet Oncol, (20180300), vol. 19, no. 3, doi:10.1016/S1470-2045(18)30081-0, pages 405 - 415, XP085355809
OPPOSITION- ATKINS et al., "Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose- expansion phase 1b trial", The LANCET Oncology, (20180210), vol. 19, no. 3, doi:10.1016/S1470-2045(18)30081-0, pages 405 - 415, XP085355809
OPPOSITION- DOLGIN, "Cancer's true breakthroughs", Nature Medicine, (20130600), vol. 19, no. 6, doi:10.1038/nm.3245, pages 660 - 663, XP055452540
OPPOSITION- Pardoll Drew M., "The blockade of immune checkpoints in cancer immunotherapy", Nature Reviews Cancer, Nature Pub. Group, London, London , (20120322), vol. 12, no. 4, doi:10.1038/nrc3239, ISSN 1474-175X, pages 252 - 264, XP037114946
OPPOSITION- PARDOLL, "The blockade of immune checkpoints in cancer immunotherapy", Nature Reviews Cancer, (20120322), vol. 12, no. 4, doi:10.1038/nrc3239, pages 252 - 264, XP037114946
OPPOSITION- KAUFMAN et al., "he society for immunotherapy of cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma", Nature Reviews Clinical Oncology, (20130000), vol. 10, doi:10.1038/nrclinonc.2013.153, pages 588 - 598, XP055632199
OPPOSITION- Mullard Asher, "Learning from the 2012-2013 class of breakthrough therapies", Nature Reviews Drug Discovery, Nature Publishing Group, GB, GB , (20131201), vol. 12, no. 12, doi:10.1038/nrd4196, ISSN 1474-1776, pages 891 - 893, XP055935185
OPPOSITION- Li Fu; Li Jingrong; Yin Ke; Zhang Juan; Li Zhen-hu; Lu Liang; Bao Yuan-wu; Qin Zhen; Zheng Yong; Yang Bao-tian; Li Jing; Wang Xinzhong, "CS1003, a novel human and mouse cross-reactive PD-1 monoclonal antibody for cancer therapy", Acta Pharmacologica Sinica, Nature Publishing Group, GB, GB , (19000101), vol. 42, no. 1, doi:10.1038/s41401-020-0422-6, ISSN 1671-4083, pages 142 - 148, XP037326108
OPPOSITION- TOPALIAN et al., "Safety, activity, and immune correlates of anti- PD-1 antibody in cancer", N. Eng. J. Med., (20120628), vol. 366, no. 26, doi:10.1056/NEJMoa1200690, pages 2443 - 2454, XP055098235
OPPOSITION- HAMID et al., "Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma", N. Engl. J. Med., (20130711), vol. 369, no. 2, doi:10.1056/NEJMoa1305133, pages 134 - 144, XP055182016
OPPOSITION- HAMID et al., "Safety and Tumor Responses with Lambrolizumab (Anti-PD-1) in Melanoma", N. Engl. J. Med., (20130711), vol. 369, no. 2, doi:10.1056/NEJMoa1305133, pages 134 - 144, XP055182016
OPPOSITION- Omid Hamid, Caroline Robert, Adil Daud, F. Stephen Hodi, Wen-Jen Hwu, Richard Kefford, Jedd D. Wolchok, Peter Hersey, Richard W. Joseph, Jeffrey S. Weber, Roxana Dronca, Tara C. Gangadhar, Amita Patnaik, Hassane Zarour, Anthony M. Joshua, Kevin Gergich, Jeroen Elassaiss-Schaap, Alain Algazi, Christine Mateus, Peter Boasberg, Paul C. Tumeh, Bartosz Chmielowski, Scot W. Ebbinghaus, Xiaoyun Nicole Li, S. Peter Kang, Antoni Ribas, "Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma", New England Journal of Medicine, New England Journal of Medicine, (20130711), vol. 369, no. 2, doi:10.1056/NEJMoa1305133, ISSN 00284793, pages 134 - 144, XP055182016
OPPOSITION- STEHLE et al., "Reduced immunosuppressive properties of axitinib in comparison with other tyrosine kinase inhibitors", J Biol Chem., (20130000), vol. 288, no. 23, doi:10.1074/jbc.M112.437962, pages 16334 - 16347, XP055632162
OPPOSITION- STEHLE et al., "Reduced immunosuppressive properties of axitinib in comparison with other tyrosine kinase inhibitors", J Biol Chem, (20130600), vol. 288, no. 23, doi:10.1074/jbc.M112.437962, pages 16334 - 16347, XP055632162
OPPOSITION- STEHLE et al., "Reduced immunosuppressive properties of axitinib in comparison with other tyrosine kinase inhibitors", J Biol Chem., (20130600), vol. 288, no. 23, doi:10.1074/jbc.M112.437962, pages 16334 - 16347, XP055632162
OPPOSITION- Stehle, Et Al., "Reduced immunosuppressive properties of axitinib in comparison with other tyrosine kinase inhibitors", J Biol Chem, (20130601), vol. 288, no. 23, doi:10.1074/jbc.M112.437962, pages 16334 - 16347, XP055632162
OPPOSITION- STEHLE et al., "Reduced Immunosuppressive Properties of Axitinib in Comparison with Other Tyrosine Kinase Inhibitors.", The Journal of Biological Chemistry, (20130607), vol. 288, no. 23, doi:10.1074/jbc.M112.437962, pages 16334 - 16347, XP055632162
OPPOSITION- Garon E.B., Gandhi L., Rizvi N., Hui R., Balmanoukian A.S., Patnaik A., Eder J.P., Blumenshein G.R., Aggarwal C., Soria J-C., Ahn M.A., Gubens M.A., Ramalingam S.S., Johnson E., Arkenau H., Lubiniecki G.M., Zhang J., Rutledge R.Z., Emancipator K., Leighl N., "Antitumor Activity of Pembrolizumab (Pembro; Mk-3475) and Correlation with Programmed Death Ligand 1 (Pd-L1) Expression in a Pooled Analysis of Patients (Pts) with Advanced Non-Small Cell Lung Carcinoma (Nsclc)", Annals of Oncology, Kluwer Dordrecht, NL, NL , (20140901), vol. 25, no. 5S, doi:10.1093/annonc/mdu438.51, ISSN 0923-7534, page v1, XP055935200
OPPOSITION- Atkins M.B., Plimack E.R., Puzanov I., Fishman M.N., Mcdermott D., Cho D.C., Vaishampayan U., George S., Olencki T., Tarazi J., Rosbrook B., Fernandez K., Keefe S., Choueiri T., "Axitinib in combination with pembrolizumab in patients (pts) with advanced renal cell carcinoma (aRCC): Preliminary safety and efficacy results", Annals of Oncology, Kluwer Dordrecht, NL, NL , (20161001), vol. 27, doi:10.1093/annonc/mdw373.01, ISSN 0923-7534, page vi266, XP055931071
OPPOSITION- 773pd, M B Atkins, E R Plimack, I Puzanov, M N Fishman, D Mcdermott, D C Cho, U Vaishampayan, S George, T Olencki, J Tarazi, B Rosbrook, K Fernandez, S Keefe, T Choueiri, Bristol-Myers Squibb, Astrazeneca, Peloton, Glaxosmithkline Merck, Acceleron, Pfizer M N Fishman, Novartis, Bayer, Merck Acceleron, Agensys J Tarazi, "genitourinary tumours, non-prostate", Annals of Oncology, doi:10.1093/annonc/mdw373.1, (20160101), pages 266 - 295, Annals of Oncology, URL: https://academic.oup.com/annonc/article-pdf/27/suppl_6/773PD/19450553/mdw373.01.pdf, XP055567647
OPPOSITION- ATKINS et al., "genitourinary tumours, non-prostate - Axitinib in combination with pembrolizumab in patients (pts)with advanced renal cell carcinoma (aRCC): Preliminary safety and efficacy results", Annals of Oncology, (20161011), vol. 27, no. 6, pages 266 - 295, XP055567647
OPPOSITION- Atkins M.B., Plimack E.R., Puzanov I., Fishman M.N., Mcdermott D., Cho D.C., Vaishampayan U., George S., Olencki T., Tarazi J., Rosbrook B., Fernandez K., Keefe S., Choueiri T., "genitourinary tumours, non-prostate - in combination with pembrolizumab in patients (pts) with advanced renal cell carcinoma (aRCC): Preliminary safety and efficacy results", Annals of Oncology, (20161001), vol. 27, no. 6, pages 266 - 295, XP055567647
OPPOSITION- Bailey A; McDermott D F, "Immune Checkpoint Inhibitors as Novel Targets for Renal Cell Carcinoma Therapeutics", CANCER JOURNAL, JONES AND BARTLETT PUBLISHERS, US, US , (20130701), vol. 19, no. 4, doi:10.1097/PPO.0b013e31829e3153, ISSN 1528-9117, pages 348 - 352, XP055632203
OPPOSITION- BAILEY AND MCDERMOTT, "Immune Checkpoint Inhibitors as Novel Targets for Renal Cell Carcinoma Therapeutics", The Cancer Journal, (20130800), vol. 19, no. 4, doi:10.1097/PPO.0b013e31829e3153, pages 348 - 352, XP055632203
OPPOSITION- BAILEY et al., "Immune Checkpoint Inhibitors as Novel Targets for Renal Cell Carcinoma Therapeutics", The Cancer Journal, (20130700), vol. 19, no. 4, doi:10.1097/PPO.0b013e31829e3153, pages 348 - 352, XP055632203
OPPOSITION- BAILEY et al., "Immune Checkpoint Inhibitors as Novel Targets for Renal Cell Carcinoma Therapeutics", The Cancer Journal, (20130800), vol. 19, no. 4, doi:10.1097/PPO.0b013e31829e3153, pages 348 - 352, XP055632203
OPPOSITION- BAILEY et al., "Immune Checkpoint Inhibitors as Novel Targets for Renal Cell Carcinoma Therapeutics", The Cancer Journal, vol. 19, no. 4, doi:10.1097/PPO.0b013e31829e3153, pages 348 - 352, XP055632203
OPPOSITION- Wirth Manfred P., Froehner Michael, "Radical prostatectomy at young age", BJU International, Blackwell Science, (20140701), vol. 114, no. 1, doi:10.1111/bju.12409, ISSN 1464-4096, pages 4 - 5, XP055935132
OPPOSITION- S. Yasuda, M. Sho, I. Yamato, H. Yoshiji, K. Wakatsuki, S. Nishiwada, H. Yagita, Y. Nakajima, "Simultaneous blockade of programmed death 1 and vascular endothelial growth factor receptor 2 (VEGFR2) induces synergistic anti-tumour effect in vivo", Clinical & Experimental Immunology, Blackwell Science Ltd., (20130601), vol. 172, no. 3, doi:10.1111/cei.12069, ISSN 00099104, pages 500 - 506, XP055180642
OPPOSITION- YASUDA et al., "Simultaneous blockade of programmed death 1 and vascular endothelial growth factor receptor 2 (VEGFR2) induces synergistic anti-tumor effect in vivo", Clin. Exp. Immunol., (20130418), vol. 172, no. 3, doi:10.1111/cei.12069, pages 500 - 506, XP055180642
OPPOSITION- YASUDA et al., "Simultaneous blockade of programmed death 1 and vascular endothelial growth factor receptor 2 (VEGFR2) induces synergistic anti-tumour effect in vivo", Clin. Exp. Immunol., (20130100), vol. 172, no. 3, doi:10.1111/cei.12069, pages 500 - 506, XP055180642
OPPOSITION- YASUDA et al., "Simultaneous blockade of programmed death 1 and vascular endothelial growth factor receptor 2 (VEGFR2) induces synergistic anti-tumour effect in vivo", Clin. Exp. Immunol., (20130418), vol. 172, no. 3, doi:10.1111/cei.12069, pages 500 - 506, XP055180642
OPPOSITION- YASUDA et al., "Simultaneous blockade of programmed death 1 and vascular endothelial growth factor receptor 2 (VEGFR2) induces synergistic anti-tumour effect in vivo", Clinical & Experimental Immunology, (20130418), vol. 172, no. 3, doi:10.1111/cei.12069, pages 500 - 506, XP055180642
OPPOSITION- YASUDA et al., "Simultaneous blockade of programmed death 1 and vascular endothelial growth factor receptor 2 (VEGFR2) induces synergistic anti-tumour effect in vivo.", Clinical & Experimental Immunology, (20130418), vol. 172, no. 3, doi:10.1111/cei.12069, pages 500 - 506, XP055180642
OPPOSITION- M. X. Sliwkowski, Mellman I., "Antibody Therapeutics in Cancer", Science, American Association for the Advancement of Science, (20130913), vol. 341, no. 6151, doi:10.1126/science.1241145, ISSN 00368075, pages 1192 - 1198, XP055079418
OPPOSITION- SLIWKOWSKI et al., "Antibody therapeutics in cancer", Science, (20130913), vol. 341, doi:10.1126/science.1241145, pages 1192 - 1198, XP055079418
OPPOSITION- D. D. Hu-Lowe, Et Al, "Nonclinical Antiangiogenesis and Antitumor Activities of Axitinib (AG-013736), an Oral, Potent, and Selective Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases 1, 2, 3", Clinical Cancer Research, Association for Cancer Research, US, US, (20081115), vol. 14, no. 22, doi:10.1158/1078-0432.CCR-08-0652, ISSN 1078-0432, pages 7272 - 7283, XP055235417
OPPOSITION- HU-LOWE et al., "Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3", Clin. Cancer Res., (20080000), vol. 14, no. 22, doi:10.1158/1078-0432.CCR-08-0652, pages 7272 - 7283, XP055235417
OPPOSITION- LIPSON et al., "Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody", Clin. Cancer Res, (20130100), vol. 19, no. 2, doi:10.1158/1078-0432.CCR-12-2625, pages 462 - 468, XP055296771
OPPOSITION- A. Patnaik, S. P. Kang, D. Rasco, K. P. Papadopoulos, J. Elassaiss-Schaap, M. Beeram, R. Drengler, C. Chen, L. Smith, G. Espino, K. Gergich, L. Delgado, A. Daud, J. A. Lindia, X. N. Li, R. H. Pierce, J. H. Yearley, D. Wu, O. Laterza, M. Lehnert, R. Iannone, A. W. Tolcher, "Phase I Study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors", Clinical Cancer Research, Association for Cancer Research, US, US, (20151001), vol. 21, no. 19, doi:10.1158/1078-0432.CCR-14-2607, ISSN 1078-0432, pages 4286 - 4293, XP055370195
OPPOSITION- PAL et al., "Novel therapies for metastatic renal cell carcinoma: Efforts to expand beyond the VEGF/mTOR signaling paradigm", Mol. Cancer Ther., (20120300), vol. 11, doi:10.1158/1535-7163.MCT-11-0806, pages 526 - 537, XP002711445
OPPOSITION- PAL et al., "Novel Therapies for Metastatic Renal Cell Carcinoma: Efforts to Expand beyond the VEGF/mTOR Signaling Paradigm", Molecular Cancer Therapeutics, (20120217), vol. 11, no. 3, doi:10.1158/1535-7163.MCT-11-0806, pages 526 - 537, XP002711445
OPPOSITION- Sumanta Kumar Pal, Stephen Williams, David Y. Josephson, Courtney Carmichael, Nicholas J. Vogelzang, David I. Quinn, "Novel Therapies for Metastatic Renal Cell Carcinoma: Efforts to Expand beyond the VEGF/mTOR Signaling Paradigm", Molecular Cancer Therapeutics, American Association for Cancer Research, US, US , (20120301), vol. 11, no. 3, doi:10.1158/1535-7163.MCT-11-0806, ISSN 1535-7163, pages 526 - 537, XP002711445
OPPOSITION- Anonymous, "PD-1 Inhibitor Becomes “Breakthrough Therapy”", CANCER DISCOVERY, American Association for Cancer Research, US, US , (20130701), vol. 3, no. 7, doi:10.1158/2159-8290.CD-NB2013-074, ISSN 2159-8274, pages OF14 - OF14, XP055935187
OPPOSITION- Rini Brian I., Grünwald Viktor, Fishman Mayer N., Melichar Bohuslav, Ueda Takeshi, Karlov Petr A, Bair A H., Chen Ying, Kim Sinil, Jonasch Eric, "Axitinib for first-line metastatic renal cell carcinoma (mRCC): Overall efficacy and pharmacokinetic (PK) analyses from a randomized phase II study.", Journal of Clinical Oncology, American Society of Clinical Oncology, US, US , (20120520), vol. 30, no. 15_suppl, doi:10.1200/jco.2012.30.15_suppl.4503, ISSN 0732-183X, pages 4503 - 4503, XP055935198
OPPOSITION- O'sullivan Ciara, Edgerly Maureen, Velarde Margarita, Wilkerson Julia, Venkatesan Aradhana M., Pittaluga Stefania, Yang Sherry X., Nguyen Dat, Balasubramaniam Sanjeeve, Fojo Tito, "The VEGF Inhibitor Axitinib Has Limited Effectiveness as a Therapy for Adrenocortical Cancer", J Clin Endocrinol Metab, (20140400), vol. 99, no. 4, pages 1291 - 1297, XP055930858
OPPOSITION- DOMBLIDES et al., "Emerging antiangiogenics for renal cancer", Expert Opin. Emerging Drugs, (20131126), vol. 18, no. 4, doi:10.1517/14728214.2013.858697, pages 495 - 511, XP055632250
OPPOSITION- Domblides, Et Al., "Emerging antiangiogenics for renal cancer", Exp. Opin. Emerg. Drugs, (20131126), vol. 18, no. 4, doi:10.1517/14728214.2013.858697, pages 495 - 511, XP055632250
OPPOSITION- DOMBLIDES et al., "Emerging antiangiogenics for renal cance r", Exp. Opin. Emerg. Drugs, (20131126), vol. 18, no. 4, doi:10.1517/14728214.2013.858697, pages 495 - 511, XP055632250
OPPOSITION- DOMBLIDES et al., "Emerging antiangiogenics for renal cancer", Exp. Opin. Emerg. Drugs, (20131126), vol. 18, no. 4, doi:10.1517/14728214.2013.858697, pages 495 - 511, XP055632250
OPPOSITION- DOMBLIDES et al., "Emerging antiangiogenics for renal cancer", Exp. Opin. Emerg. Drugs., (20131126), vol. 18, no. 4, doi:10.1517/14728214.2013.858697, pages 495 - 511, XP055632250
OPPOSITION- DORFF et al., "Novel tyrosine kinase inhibitors for renal cell carcinoma", J. Exp. Rev. Clin. Pharmacol., (20131202), vol. 7, no. 1, doi:10.1586/17512433.2014.862496, pages 67 - 73, XP055632245
OPPOSITION- DORFF et al., "Novel tyrosine kinase inhibitors for renal cell carcinoma", J. Exp. Rev. Clin. Pharmacol., vol. 7, no. 1, doi:10.1586/17512433.2014.862496, (20131202), pages 67 - 73, XP055632245
OPPOSITION- Tanya B Dorff, Sumanta K Pal, David I Quinn, "Novel tyrosine kinase inhibitors for renal cell carcinoma", Expert Review of Clinical Pharmacology 20141101 Expert Reviews Ltd. gbr, Taylor & Francis, UK, UK , (20140101), vol. 7, no. 1, doi:10.1586/17512433.2014.862496, ISSN 1751-2433, pages 67 - 73, XP055632245
OPPOSITION- Van Geel, Et Al., "Concise drug review: Pazopanib and axitinib", Oncologist, (20120625), vol. 17, doi:10.1634/theoncologist.2012-0055, pages 1081 - 1089, XP055632159
OPPOSITION- VAN GEEL et al., "Concise drug review: Pazopanib and axitinib", Oncologist, (20120625), vol. 17, doi:10.1634/theoncologist.2012-0055, pages 1081 - 1089, XP055632159
OPPOSITION- VAN GEEL et al., "Concise Drug Review: Pazopanib and Axitinib", Oncologist, vol. 17, no. 8, doi:10.1634/theoncologist.2012-0055, (20120625), pages 1081 - 1089, XP055632159
OPPOSITION- VAN GEEL et al., "Concise Drug Review: Pazopanib and Axitinib.", The Oncologist, (20120625), vol. 17, doi:10.1634/theoncologist.2012-0055, pages 1081 - 1089, XP055632159
OPPOSITION- VAN GEEL et al., "Concise drug review: Pazopanib and axitinib", The Oncologist 2012, vol. 17, doi:10.1634/theoncologist.2012-0055, pages 1081 - 1089, XP055632159
OPPOSITION- BAI et al., "A guide to rational dosing of monoclonal antibodies", Clin Pharmacokinet., (20120200), vol. 51, no. 2, doi:10.2165/11596370-000000000-00000, pages 119 - 35, XP009184175
OPPOSITION- Scott S Tykodi, "Progress and potential of immune checkpoint blockade for treating advanced renal cell carcinoma", Immunother, (20130603), vol. 5, no. 6, doi:10.2217/imt.13.39, pages 607 - 619, XP055632192
OPPOSITION- TYKODI, "Progress and potential of immune checkpoint blockade for treating advanced renal cell carcinoma", Immunother, (20130603), vol. 5, no. 6, doi:10.2217/imt.13.39, pages 607 - 619, XP055632192
OPPOSITION- TYKODI, "Progress and potential of immune checkpoint blockade for treating advanced renal cell carcinoma", Immunother, (20130603), vol. 5, no. 6, doi:10.2217/imt.13.39, pages 607 - 919, XP055632192
OPPOSITION- TYKODI, "Progress and potential of immune checkpoint blockade for treating advanced renal cell carcinoma", Immunotherapy, (20130603), vol. 5, no. 6, doi:10.2217/imt.13.39, pages 607 - 619, XP055632192
OPPOSITION- Pantelyushin Stanislav, Ranninger Elisabeth, Guerrera Diego, Hutter Gregor, Maake Caroline, Markkanen Enni, Bettschart-Wolfensberger Regula, Rohrer Bley Carla, Läubli Heinz, Vom Berg Johannes, "Cross-Reactivity and Functionality of Approved Human Immune Checkpoint Blockers in Dogs", Cancers, MDPI AG, CH, CH , vol. 13, no. 4, doi:10.3390/cancers13040785, ISSN 2072-6694, page 785, XP093155884
OPPOSITION- GROSS-GOUPIL et al., "Axitinib: A Review of its Safety and Efficacy in the Treatment of Adults with Advanced Renal Cell Carcinoma", Clin Med Insights Oncol, (20131029), vol. 7, pages 269 - 277, XP055928382
OPPOSITION- Gross-Goupil Marine, Françlois Louis, Quivy Amandine, Ravaud Alain, "Axitinib: A Review of its Safety and Efficacy in the Treatment of Adults with Advanced Renal Cell Carcinoma", Clinical Medicine Insights: Oncology, (20130000), vol. 7, pages 269 - 277, XP055928382
OPPOSITION- Gross-Goupil Marine, Françlois Louis, Quivy Amandine, Ravaud Alain, "Axitinib: A Review of its Safety and Efficacy in the Treatment of Adults with Advanced Renal Cell Carcinoma", Clinical Medicine Insights: Oncology, Libertas Academica Ltd., NZL, NZL , (20130101), vol. 7, doi:10.4137/CMO.S10594, ISSN 1179-5549, page CMO.S10594, XP055928382
SEARCH- Anonymous, "NCT02014636 A Phase I/II Study to Assess the Safety and Efficacy of Pazopanib and MK 3475 in Subjects With Advanced Renal Cell Carcinoma", Clinical Trials.gov, (20140124), pages 1 - 11, URL: https://clinicaltrials.gov/archive/NCT02014636/2014_01_24, (20150331), XP055180536 [A] 1-15 * the whole document *
SEARCH- Clinicaltrials, "NCT02133742, A Dose Finding Study To Evaluate Safety, Drug Interaction, Tumor Markers Of Axitinib In Combination With MK-3475 In Adult Patients With Previously Untreated Advanced Renal Cell Cancer", ClinicalTrials.gov archive, (20140705), URL: https://clinicaltrials.gov/archive/NCT02133742/2014_05_07, (20150330), XP055180147 [PX] 1-15 * the whole document *
SEARCH- DAVID F. MCDERMOTT ET AL, "PD-1 as a potential target in cancer therapy", CANCER MEDICINE, (20130721), doi:10.1002/cam4.106, ISSN 2045-7634, pages 662 - 673, XP055157252 [A] 1-15 * page 669, column r, paragraph l - page 670, column l, paragraph 2 *
SEARCH- BERNARD ESCUDIER ET AL, "Axitinib for the Management of Metastatic Renal Cell Carcinoma", DRUGS IN R&D, (20110601), vol. 11, no. 2, doi:10.1007/BF03259801, ISSN 1174-5886, pages 113 - 126, XP055180526 [A] 1-15 * the whole document *
SEARCH[ ] - ATKINS MICHAEL B ET AL, "Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial", THE LANCET ONCOLOGY, ELSEVIER, AMSTERDAM, NL, (20180210), vol. 19, no. 3, doi:10.1016/S1470-2045(18)30081-0, ISSN 1470-2045, pages 405 - 415, XP085355809
SEARCH[ ] - Atkins, "Axitinib in combination with pembrolizumab in patients (pts)with advanced renal cell carcinoma (aRCC): Preliminarysafety and efficacy results", Annals of Oncology, doi:10.1093/annonc/mdw373.1, (20161011), pages 266 - 295, ESMO 2016 CONGRESS, 09.10.2016,, URL: https://doi.org/10.1093/annonc/mdw373.01, XP055567647
SEARCH- S. YASUDA ET AL, "Simultaneous blockade of programmed death 1 and vascular endothelial growth factor receptor 2 (VEGFR2) induces synergistic anti-tumour effect in vivo", CLINICAL & EXPERIMENTAL IMMUNOLOGY, (20130418), vol. 172, no. 3, doi:10.1111/cei.12069, ISSN 0009-9104, pages 500 - 506, XP055180642 [A] 1-15 * page 501, column l, paragraph 5 * * paragraph [results] - paragraph [discussion]; figure 2 *

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents